xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06028451</url>
    </required_header>
    <id_info>
      <org_study_id>2023ZDYYLL01</org_study_id>
      <nct_id>NCT06028451</nct_id>
    </id_info>
    <brief_title>ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study</brief_title>
    <official_title>ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Southeast University, China</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Southeast University, China</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        To assessed the current situation and outcome of critically ill patients with invasive&#xD;
        aspergillus infection.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        To assessed the current situation and outcome of critically ill patients with invasive&#xD;
        aspergillus infection.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 15, 2023</start_date>
    <completion_date type="Anticipated">December 15, 2024</completion_date>
    <primary_completion_date type="Anticipated">September 15, 2024</primary_completion_date>
    <study_type>Observational [Patient Registry]</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <target_duration>90 Days</target_duration>
    <primary_outcome>
      <measure>mortality</measure>
      <time_frame>28 day</time_frame>
    </primary_outcome>
    <number_of_groups>2</number_of_groups>
    <enrollment type="Anticipated">550</enrollment>
    <condition>Invasive Aspergillosis</condition>
    <arm_group>
      <arm_group_label>Survivors</arm_group_label>
      <description>Critically ill patients with invasive aspergillus infection who survived</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Nonsurvivors</arm_group_label>
      <description>Critically ill patients with invasive aspergillus infection who not survived</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Record the information data</intervention_name>
      <description>Record the information data</description>
      <arm_group_label>Nonsurvivors</arm_group_label>
      <arm_group_label>Survivors</arm_group_label>
    </intervention>
    <eligibility>
      <study_pop>
        <textblock>
          Patients diagosed as invasive aspergillosis&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age&gt;18 year-old Diagosed as invasive aspergillus infection&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Pregnant&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 31, 2023</study_first_submitted>
    <study_first_submitted_qc>August 31, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 8, 2023</study_first_posted>
    <last_update_submitted>August 31, 2023</last_update_submitted>
    <last_update_submitted_qc>August 31, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 8, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Southeast University, China</investigator_affiliation>
      <investigator_full_name>Jingyuan,Xu</investigator_full_name>
      <investigator_title>Principal Investigator</investigator_title>
    </responsible_party>
    <keyword>invasive aspergillus infection</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Aspergillosis</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06028451
  org study id: 2023ZDYYLL01
  nct id: NCT06028451
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  To assessed the current situation and outcome of critically ill patients with invasive
        aspergillus infection.
  To assessed the current situation and outcome of critically ill patients with invasive
        aspergillus infection.
  observational model: Cohort
  time perspective: Prospective
  measure: mortality
  time frame: 28 day
  arm group label: Survivors
  description: Critically ill patients with invasive aspergillus infection who survived
  arm group label: Nonsurvivors
  description: Critically ill patients with invasive aspergillus infection who not survived
  intervention type: Other
  intervention name: Record the information data
  description: Record the information data
  arm group label: Nonsurvivors
  arm group label: Survivors
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  responsible party type: Principal Investigator
  investigator affiliation: Southeast University, China
  investigator full name: Jingyuan,Xu
  investigator title: Principal Investigator
  mesh term: Aspergillosis
  sharing ipd: Undecided